Work

Mutein IL-2 Attenuates Antigen-Mediated Rejection in Murine Kidney Transplant Model

Year: 2025

Type: article

Abstract: Purpose: Antibody-mediated chronic rejection (AMR) remains a major obstacle to long-term graft survival, necessitating the development of more effective therapies. Selective in vivo expansion of regulatory T cells (Tregs) using low-dose IL-2 or its analogs has emerged as a promising strategy for promoting graft acceptance. We previously demonstrated a novel IL-2 mutein (mIL-2), engineered for greater Treg selectivity and improved bioavailability, suppresses T cell-mediated acute rejection through Treg expansion.

Source: American Journal of Transplantation

DOI: 10.1016/j.ajt.2025.07.705

Authors: Y. Ganchiku, R.B. Gassen, Z. Shriver, G.J. Babcock, T.J. Borges, L.V. Riella

Institutions: Massachusetts General Hospital, Visterra (United States)

Language: English

Topic: Renal Transplantation Outcomes and Treatments

Subfield: Transplantation

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $4,300